Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2010 1
2014 1
2015 1
2016 1
2017 1
2018 1
2019 1
2020 1
2021 2
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
The following terms were ignored: %, %
The following terms were not found in PubMed: 5Bsubset
Page 1
Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic triple-negative breast cancer that expresses PD-L1.
Huang M, O'Shaughnessy J, Haiderali A, Pan W, Hu P, Chaudhuri M, Le Bailly De Tilleghem C, Cappoen N, Fasching PA. Huang M, et al. Eur J Cancer. 2022 Dec;177:45-52. doi: 10.1016/j.ejca.2022.09.029. Epub 2022 Oct 3. Eur J Cancer. 2022. PMID: 36323052 Clinical Trial.
Patients' survival time was partitioned into three health states - toxicity before disease progression (TOX), time without symptoms or toxicity before disease progression (TWiST), and relapse (REL). Utilities for these health states were estimated using EuroQol-5 Dimension …
Patients' survival time was partitioned into three health states - toxicity before disease progression (TOX), time without symptoms o …
Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2- Advanced Breast Cancer in the MONALEESA-3 Trial.
Jerusalem G, Delea TE, Martin M, De Laurentiis M, Nusch A, Beck JT, Chan A, Im SA, Neven P, Lonshteyn A, Chandiwana D, Lanoue B, Fasching PA. Jerusalem G, et al. Clin Breast Cancer. 2022 Jun;22(4):326-335. doi: 10.1016/j.clbc.2021.12.008. Epub 2021 Dec 20. Clin Breast Cancer. 2022. PMID: 35034858 Clinical Trial.
METHODS: Kaplan-Meier OS was partitioned into health states: (1) toxicity (TOX)=time spent with grade 3 -4 adverse events before progression (DP); (2) progression (PROG)=time between DP and death; and (3) time without symptoms or toxicity (TWiST)=time not in TOX or …
METHODS: Kaplan-Meier OS was partitioned into health states: (1) toxicity (TOX)=time spent with grade 3 -4 adverse events before prog …
Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma.
Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cella D, Meunier J, Goble S, Cameron T, Maloney L, Mörk AC, Bedel J, Ledermann JA, Coleman RL. Oza AM, et al. J Clin Oncol. 2020 Oct 20;38(30):3494-3505. doi: 10.1200/JCO.19.03107. Epub 2020 Aug 24. J Clin Oncol. 2020. PMID: 32840418 Free PMC article.
QA-PFS was calculated as progression-free survival function the 3-level version of the EQ-5D questionnaire (EQ-5D-3L) index score function. Q-TWiST analyses were performed defining TOX as the mean duration in which a patient experienced grade 3 treatment-emer …
QA-PFS was calculated as progression-free survival function the 3-level version of the EQ-5D questionnaire (EQ-5D-3L) index sc …
Design, synthesis, characterization, and antioxidant activity studies of novel thienyl-pyrazoles.
Kumara K, Prabhudeva MG, Vagish CB, Vivek HK, Lokanatha Rai KM, Lokanath NK, Ajay Kumar K. Kumara K, et al. Heliyon. 2021 Jul 15;7(7):e07592. doi: 10.1016/j.heliyon.2021.e07592. eCollection 2021 Jul. Heliyon. 2021. PMID: 34355092 Free PMC article.
Structure proofs of new pyrazoles offered by spectral studies, and the molecular structure of compound 5d of the series by crystallographic studies, which revealed an intra molecular hydrogen bond interactions (C-HN type), and stabilization by C-H...pi and pi---pi molecula …
Structure proofs of new pyrazoles offered by spectral studies, and the molecular structure of compound 5d of the series by crystallog …
Chromone-isoxazole hybrids molecules: synthesis, spectroscopic, MEDT, ELF, antibacterial, ADME-Tox, molecular docking and MD simulation investigations.
Kanzouai Y, Laghmari M, Yamari I, Bouzammit R, Bahsis L, Benali T, Chtita S, Bakhouch M, Akhazzane M, El Kouali M, Hammani K, Al Houari G. Kanzouai Y, et al. J Biomol Struct Dyn. 2023 Oct 10:1-15. doi: 10.1080/07391102.2023.2266022. Online ahead of print. J Biomol Struct Dyn. 2023. PMID: 37817499
In silico studies on the pharmacokinetics, ADME and toxicity tests of the compounds were also performed, and it was projected that compounds 5a, 5b, 5c and 5d are pharmacokinetic and have favorable ADME profiles. Moreover, docking and molecular dynamics investigations were …
In silico studies on the pharmacokinetics, ADME and toxicity tests of the compounds were also performed, and it was projected that compounds …
Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis.
McDermott DF, Shah R, Gupte-Singh K, Sabater J, Luo L, Botteman M, Rao S, Regan MM, Atkins M. McDermott DF, et al. Qual Life Res. 2019 Jan;28(1):109-119. doi: 10.1007/s11136-018-1984-3. Epub 2018 Sep 6. Qual Life Res. 2019. PMID: 30191365 Clinical Trial.
Mean quality-adjusted TWiST (Q-TWiST) was calculated by multiplying the mean time spent in each health state by a utility of 1.0 for TWiST and 0.5 for TOX and REL. Sensitivity analyses included varying utilities of TOX and REL; Q-TWiST gains at different follow-up t …
Mean quality-adjusted TWiST (Q-TWiST) was calculated by multiplying the mean time spent in each health state by a utility of 1.0 for TWiST a …
Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma.
Zbrozek AS, Hudes G, Levy D, Strahs A, Berkenblit A, DeMarinis R, Parasuraman S. Zbrozek AS, et al. Pharmacoeconomics. 2010;28(7):577-84. doi: 10.2165/11535290-000000000-00000. Pharmacoeconomics. 2010. PMID: 20550223 Clinical Trial.
METHODS: Overall survival was partitioned into three distinct health states: time with serious toxicity (TOX), time after progression (REL) and time without symptoms of progression or toxicity (TWiST). ...EQ-5D questionnaires were obtained from 260 patients upon pro …
METHODS: Overall survival was partitioned into three distinct health states: time with serious toxicity (TOX), time after progression …
Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer.
Sherrill B, Amonkar MM, Stein S, Walker M, Geyer C, Cameron D. Sherrill B, et al. Br J Cancer. 2008 Sep 2;99(5):711-5. doi: 10.1038/sj.bjc.6604501. Epub 2008 Aug 19. Br J Cancer. 2008. PMID: 18728660 Free PMC article. Clinical Trial.
The area under survival curves was partitioned into health states: toxicity (TOX), time without symptoms of disease progression or toxicity (TWiST), and relapse period until death or end of follow-up (REL). Average times spent in each state, weighted by utility, were deriv …
The area under survival curves was partitioned into health states: toxicity (TOX), time without symptoms of disease progression or to …
11 results